Business Description
Vertex Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US92532F1003
Share Class Description:
MEX:VRTX: Ordinary SharesCompare
Compare
Traded in other countries / regions
VRTX.USAVRTX.MexicoVX1.GermanyVRTX34.BrazilVRTX.Austria1VRTX.ItalyVX1d.UK IPO Date
2013-06-18Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.88 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | 0.18 | |||||
| Interest Coverage | 97.68 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 14.3 | |||||
| Beneish M-Score | -2.04 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 17.2 | |||||
| 3-Year EBITDA Growth Rate | 12.3 | |||||
| 3-Year EPS without NRI Growth Rate | 13.8 | |||||
| 3-Year FCF Growth Rate | 3.5 | |||||
| 3-Year Book Growth Rate | 26.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 12.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 8.83 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.08 | |||||
| 9-Day RSI | 42.31 | |||||
| 14-Day RSI | 40 | |||||
| 6-1 Month Momentum % | 3.24 | |||||
| 12-1 Month Momentum % | 18.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.99 | |||||
| Quick Ratio | 3.78 | |||||
| Cash Ratio | 3.16 | |||||
| Days Inventory | 175.05 | |||||
| Days Sales Outstanding | 56.57 | |||||
| Days Payable | 100.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | 0.71 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 87.21 | |||||
| Operating Margin % | 43.65 | |||||
| Net Margin % | 36.68 | |||||
| FCF Margin % | 33.3 | |||||
| ROE % | 23.23 | |||||
| ROA % | 17.76 | |||||
| ROIC % | 50.94 | |||||
| ROC (Joel Greenblatt) % | 305.61 | |||||
| ROCE % | 25.82 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 28.79 | |||||
| Forward PE Ratio | 23.92 | |||||
| PE Ratio without NRI | 25.15 | |||||
| Shiller PE Ratio | 68.26 | |||||
| Price-to-Owner-Earnings | 36.81 | |||||
| PEG Ratio | 0.61 | |||||
| PS Ratio | 10.56 | |||||
| PB Ratio | 5.86 | |||||
| Price-to-Tangible-Book | 6.58 | |||||
| Price-to-Free-Cash-Flow | 31.77 | |||||
| Price-to-Operating-Cash-Flow | 29.44 | |||||
| EV-to-EBIT | 21.01 | |||||
| EV-to-Forward-EBIT | 18.7 | |||||
| EV-to-EBITDA | 20.18 | |||||
| EV-to-Forward-EBITDA | 17.81 | |||||
| EV-to-Revenue | 9.42 | |||||
| EV-to-Forward-Revenue | 8.67 | |||||
| EV-to-FCF | 28.34 | |||||
| Price-to-Projected-FCF | 2.05 | |||||
| Price-to-Median-PS-Value | 0.71 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.01 | |||||
| Price-to-Graham-Number | 2.71 | |||||
| Price-to-Net-Current-Asset-Value | 11.46 | |||||
| Price-to-Net-Cash | 16.98 | |||||
| Earnings Yield (Greenblatt) % | 4.76 | |||||
| FCF Yield % | 3.17 | |||||
| Forward Rate of Return (Yacktman) % | 22.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vertex Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 172,922.435 | ||
| EPS (TTM) (MXN) | 242.647 | ||
| Beta | -0.22 | ||
| Volatility % | 23.71 | ||
| 14-Day RSI | 40 | ||
| 14-Day ATR (MXN) | 50.757644 | ||
| 20-Day SMA (MXN) | 6780.465 | ||
| 12-1 Month Momentum % | 18.5 | ||
| 52-Week Range (MXN) | 5665 - 7607.96 | ||
| Shares Outstanding (Mil) | 258.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vertex Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vertex Pharmaceuticals Inc Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vertex Pharmaceuticals Inc Frequently Asked Questions
What is Vertex Pharmaceuticals Inc(MEX:VRTX)'s stock price today?
The current price of MEX:VRTX is MXN6676.00. The 52 week high of MEX:VRTX is MXN7607.96 and 52 week low is MXN5665.00.
When is next earnings date of Vertex Pharmaceuticals Inc(MEX:VRTX)?
The next earnings date of Vertex Pharmaceuticals Inc(MEX:VRTX) is 2024-05-06.
Does Vertex Pharmaceuticals Inc(MEX:VRTX) pay dividends? If so, how much?
Vertex Pharmaceuticals Inc(MEX:VRTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers